Literature DB >> 19727961

Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy.

Michelle D Williams1, James W Suliburk, Gregg A Staerkel, Naifa L Busaidy, Gary L Clayman, Douglas B Evans, Nancy D Perrier.   

Abstract

BACKGROUND: Subclassifying indeterminate thyroid fine-needle aspiration (FNA) biopsy findings as follicular lesion or follicular neoplasm has been suggested as useful in triaging patients to observation or surgery, respectively. However, terminology and therefore the probability of malignancy vary between pathologists and institutions. The purpose of this study was to evaluate a single institution's experience with indeterminate thyroid FNA results to determine if subclassification (neoplasm versus lesion) aids in identifying patients at higher risk for malignancy.
METHODS: From 1990 to 2006, all patients with indeterminate thyroid FNA results (follicular lesion or neoplasm) at The University of Texas M.D. Anderson Cancer Center were evaluated for FNA correlation with the surgical specimen diagnosis. Patients with FNAs suspicious for papillary thyroid carcinoma or with definitive malignant disease (i.e., metastases) were excluded.
RESULTS: Indeterminate FNA results were present in 540 patients, including 410 as follicular lesion and 130 as follicular neoplasm. Two hundred ninety-seven (55.0%) patients underwent surgical resection: 199 (48.5%) follicular lesions and 98 (75.4%) follicular neoplasms. Incidence of malignancy was higher in thyroid nodules classified as neoplasm compared with lesion (21.4% versus 7.0%, respectively; P=0.0005) and increased in follicular neoplasms with nodule size (37.5% malignant if nodule was [4 cm, P=0.03).
CONCLUSIONS: Subclassification of indeterminate thyroid FNA biopsy results into neoplasm and lesion successfully defines high- and low-risk nodules, respectively. These findings support surgical resection for follicular neoplasms, selective use of surgical intervention for follicular lesions at our institution, and continued efforts to define unified terminology between institutions.

Entities:  

Mesh:

Year:  2009        PMID: 19727961     DOI: 10.1245/s10434-009-0666-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas.

Authors:  Michelle D Williams; Li Zhang; Danielle D Elliott; Nancy D Perrier; Guillermina Lozano; Gary L Clayman; Adel K El-Naggar
Journal:  Hum Pathol       Date:  2011-03-21       Impact factor: 3.466

2.  A meta-analysis examining the independent association between thyroid nodule size and malignancy.

Authors:  AbdulRahman Y Hammad; Salem I Noureldine; Tian Hu; Yasin Ibrahim; Hammad M Masoodi; Emad Kandil
Journal:  Gland Surg       Date:  2016-06

Review 3.  Progress in molecular-based management of differentiated thyroid cancer.

Authors:  Mingzhao Xing; Bryan R Haugen; Martin Schlumberger
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

4.  Follicular variant of papillary thyroid carcinoma: accuracy of FNA diagnosis and implications for patient management.

Authors:  Berrin Ustun; David Chhieng; Manju L Prasad; Elizabeth Holt; Lynwood Hammers; Tobias Carling; Robert Udelsman; Adebowale J Adeniran
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

5.  Subclassification of follicular neoplasms recommended by the Japan thyroid association reporting system of thyroid cytology.

Authors:  Kennichi Kakudo; Kaori Kameyama; Mitsuyoshi Hirokawa; Ryohei Katoh; Hirotoshi Nakamura
Journal:  Int J Endocrinol       Date:  2015-02-04       Impact factor: 3.257

6.  Cytomorphological Categorization of Thyroid Lesions according to The Bethesda System for Reporting Thyroid Cytology and Correlation with their Histological Outcome: An Indian Oncology Centre Experience.

Authors:  Meenakshi Kamboj; Anurag Mehta; Sunil Pasricha; Gurudutt Gupta; Anila Sharma; Garima Durga
Journal:  J Cytol       Date:  2022-01-31       Impact factor: 1.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.